乌司他丁对二尖瓣置换术患者围术期内皮糖萼及肺功能的影响

目的：观察乌司他丁对二尖瓣置换术患者围术期内皮糖萼的影响及其肺保护作用。方法：选择择期行二 尖瓣置换术患者40例，随机分为对照组(20例)和乌司他丁组(20例)，分别在体外循环开始时给予生理盐水50 mL或乌 司他丁2×104 U/kg。观察切皮前(T0)，体外循环10 min(T1)，停止体外循环后1 h(T2)，术后8 h(T3)时患者动脉血中内 皮糖萼成分syndecan-1和抗肿瘤坏死因子(TNF-α)水平；T0，T2及T3时氧合指数(oxygenation index，OI)、肺泡动脉血 氧分压差(diff erence of alveolar arterial oxygen partial pressure，PA-aO2)。结果：在T0时，血浆syndecan-1和TNF-α含量，以 及OI和PA-aO2，对照组和乌司他丁组间差异无统计学意义(P>0.05)；两组在T1和T2时syndecan-1和TNF-α含量较T0时均 升高，在T2时达高峰；与对照组比较，乌司他丁组在T1，T2和T3时syndecan-1和TNF-α含量均降低(P<0.05)。与T0相 比，在T2和T3时，两组患者OI均降低，PA-aO2均升高，但乌司他丁组较对照组明显改善(P<0.05)。结论：乌司他丁可 改善二尖瓣置换患者术后肺换气功能，其机制可能与其抑制TNF-α释放，减少血管内皮糖萼脱落有关。

Effect of ulinastatin on perioperative glycocalyx and lung function in patients undergoing mitral valve replacement surgery

Objective: To explore the effect of ulinastatin on perioperative glycocalyx and lung function in patients undergoing mitral valve replacement surgery. Methods: Fourty patients, undergoing mitral valve replacement, were randomly allocated into a control group and an ulinastatin group, which were administrated 50 mL normal saline or 2×104 U/kg ulinastatin at the beginning of cardiopulmonary bypass (CPB), respectively. Th e radical artery blood was collected at 4 time points: Aft er induction of anesthesia (T0), at 10 min aft er thestart of CPB (T1), 1 h after the end of CPB (T2), and 8 h after operation. The concentration of syndecan-1 and TNF-α in blood was measured. Moreover, the blood gas analysis was preformed and the oxygen index (OI) and difference in alveolar arterial oxygen partial pressure (PA-aO2) were calculated at T0, T2, and T3. Results: There were no significant difference between the 2 groups in OI, PA-aO2, and the concentration of syndecan-1 and TNF-α at T0 (P>0.05). The concentration of syndecan-1 and TNF-α was significantly increased at T1 and T2 in the 2 groups, and reached peak at T2. Compared with the control group, the concentration of syndecan-1 and TNF-α was decreased in the ulinastatin group at T1, T2, and T3 (P<0.05). Compared with T0, OI was lower and PA-aO2 was higher at T2 and T3 in both groups, but the 2 indexes were improved in the ulinastatin group compared with those in the control group (P<0.05). Conclusion: Ulinastatin can improve the post-operative pulmonary ventilation function in patients with mitral valve replacement. The mechanism may be associated with the inhibition of TNF-α release and the reduction of glycocalyx shedding induced by ulinastatin.